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Abstract
Background: A previous systematic review and meta-analysis reported that omega-3 fatty acids nutrition may
reduce mortality in septic patients. As new randomized controlled trials began to accumulate, we conducted an
update.
Methods: A PubMed database was searched through Feb 2016, and randomized controlled trials comparing
omega-3 fatty acids with control were selected by two reviewers independently.
Results: Eleven trials randomly assigning 808 patients were included in the present study. Using a fixed effects
model, we found no significant effect of omega-3 fatty acids on overall mortality (risk ratio 0.84; 95 % confidence
interval (CI): 0.67 to 1.05, P = 0.12), or infectious complications (risk ratio 0.95; 95 % CI: 0.72 to 1.25, P = 0.70).
However, the duration of mechanical ventilation was markedly reduced by omega-3 fatty acids (weighted mean
differences (WMD) = −3.82; 95 % CI: −4.61 to −3.04; P < 0.00001). A significant heterogeneity was found when the
duration of hospital (I2 = 93 %; WMD = −2.82; 95 % CI: −9.88 to 4.23, P = 0.43), or intensive care stay (I2 = 87 %;
WMD = −2.70; 95 % CI: −6.40 to 1.00, P = 0.15) were investigated.
Conclusions: Omega-3 fatty acids confer no mortality benefit but are associated with a reduction in
mechanical ventilation duration in septic patients. However, low sample size and heterogeneity of the cohorts
included in this analysis limits the generalizability of our findings.
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Background
Sepsis is a life threatening systemic inflammatory syn-
drome that is triggered by infection, and it is a major
cause of death in critical ill patients such as severe burn
[1, 2]. Even with dramatic advances in pharmacology as
well as the technology of intensive care and life support-
ing, the mortality estimates in septic patients is as high
as over 25 % [1]. It is suggested that when complicated
with organ failure or shock, the mortality in septic pa-
tients could be further elevated to 33.2 % [3–5]. Thus,
strategies that could play a benefit on survival in septic
patients are appreciated.
Omega-3 fatty acids are reported to have a protective
role in cardiovascular diseases [6]. And it is also recog-
nized that omega-3 fatty acids have anti-inflammatory
and immunomodulating features [7]. Recently, a number
of studies have focused on the effect of omega-3 fatty
acids on septic patients [8–17]. However, inconsistent
findings were reported between trials. A systematic re-
view and meta-analysis published in 2014 found mortal-
ity in septic patients could be reduced by parenteral
nutrition of omega-3 fatty acids [18]. However, as the
low quality of enrolled trials, the authors concluded that
the effect of omega-3 fatty acids on the mortality of sep-
sis was uncertain [18]. Meanwhile, as new randomized
controlled trials began to accumulate, we conducted an
update and in the present meta-analysis, our goal was to
evaluate the effect of omega-3 fatty acids nutrition on
mortality, the duration of hospital, intensive care unit
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(ICU) stay, infectious complications, and the duration of
mechanical ventilation in septic patients.
Methods
Search strategy
The present study was conducted according to the Pre-
ferred Reporting Items for Systematic reviews and Meta
Analysis (PRISMA) of randomized controlled trials [19].
We conducted an electronic search of PubMed database
up to Feb 2016 for relevant studies that tested the effect
of omega-3 fatty acids enriched nutrition on septic pa-
tients. And we limited citations to prospective random-
ized controlled trials in adults. The following search
terms were used: 1) omega-3 fatty acids, fish oil, eicosa-
pentaenoic acid, or docosahexaenoic acid; 2) sepsis, se-
vere sepsis, or septic shock. In order to identify other
potentially eligible studies that had not been captured
with our primary electronic search, the reference lists of
retrieved published papers and recent reviews were also
reviewed. The literature language was restricted to
English.
Study selection
Two investigators (WT and ZS) reviewed studies for
inclusion, retrieved potentially relevant studies, and de-
cided on study eligibility independently. Any differences
were resolved by consensus. Agreements of trial eligibil-
ity between reviewers were assessed by using Cohen’s k
[20]. As the current meta-analysis was based on trials
which published previously, no ethical approval or pa-
tient consent was required.
Inclusion criteria
Studies were considered eligible if the following criteria
were present: 1) the study design was a randomized con-
trolled trial in adults (≥18 years of age); 2) subjects were
patients with sepsis, severe sepsis, or septic shock [21];
3) the study compared omega-3 fatty acids enriched nu-
trition (administrated via either parenteral or enteral
route) with control (septic patients treated with an
omega-3 fatty acids deficiency nutrition) ; 4) the mortal-
ity (at 28-days or, if not available, mortality at any time
was recorded), the length of ICU stay, the duration of
hospital, infectious complications, or the duration of
mechanical ventilation was reported.
Exclusion criteria
The exclusion criterion was: using healthy people as
control, administration strategies were different between
study and control group, the article was a review, editor-
ial, children’s research, animal study, letter or other type
of publication not based on original research, or the
study did not include extractable outcomes.
Data extraction and quality assessment
The following items from the each study were extracted
into standardized data abstraction forms by two re-
viewers (WT and ZS) independently: first author’s last
name, publication year, sample size, country of origin,
the composition of nutrition, administration strategies,
and secondary organ dysfunction. The primary outcome
was mortality. The secondary outcomes were the length
of ICU stay, the duration of hospital stay, infectious com-
plications, and the duration of mechanical ventilation.
The methodological quality of each trial was evaluated by
two of the researchers (WT and ZS) independently, and
the Jadad’s scale and Cochrane Handbook for risks of bias
assessments were used [22, 23].
Statistical analysis
RevMan software (version 5.3.5) was used in our meta-
analysis. We reported binary outcomes as risk ratios
(RR) and continuous outcomes as weighted mean differ-
ences (WMD). Summary effect estimates were presented
with 95 % confidence interval (CI). Heterogeneity was
explored for all the meta-analysis. Statistical heterogen-
eity was measured and quantified using the I2 test and
the Mantel–Haenszel χ2 test. Statistical heterogeneity
was predefined at I2 > 50 % or P < 0.05 by Mantel–
Haenszel χ2 test. We reported results from a fixed effect
model if there was no statistical heterogeneity (P ≥ 0.05
or I2 ≤ 50 %), or, a randomized effect model was used.
Publication bias was assessed for all analysis after visual
inspection of funnel plots. The Cohen’s k was used to as-
sess the agreements between reviewers for trial eligibility
and methodological quality assessment [20].
Results
Search results
256 potentially relevant articles were identified after an
electronic searching from among 255 listed in the
PubMed database, and one article after evaluating the
reference lists of retrieved reviews. Most of the 256 arti-
cles were excluded for reasons such as studies of chil-
dren, reviews, not relevant to our meta-analysis, or
animal studies after screening titles and abstracts. Then,
fourteen relevant trials were yielded [8–17, 24–27]. After
a full-text assessment, three trials [24, 25, 27] were ex-
cluded for reasons such as using healthy people as con-
trol [24, 25], comparing enteral with parenteral nutrition
of omega-3 fatty acids not control (septic patients
treated with an omega-3 fatty acids deficiency nutrition)
[27] (Fig. 1). Finally, we included eleven randomized
controlled trials [8–17, 26] in the present meta-analysis
which were completely agreed by two reviewers (k = 1).
We excluded 8 trials that included in a previous meta-
analysis [18] based on our inclusion and exclusion cri-
teria (5 published in Chinese language, two using healthy
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people as control, one was published as abstracts).
Our study included four trials [8, 12, 13, 17] investi-
gated the effect of enteral omega-3 fatty acids nutri-
tion on septic patients. And three new randomized
controlled trials [9–11] investigate parenteral nutrition
were included in the present meta-analysis. Figure 1
shows a flowchart of study selection at different
stages of the meta-analysis.
Characteristics and the quality of studies
The included eleven trials were published from 2003 to
2015 and enrolled an aggregate of 808 patients, including
405 patients in the study group and 403 in the control
group. We did not have access to primary data and there-
fore were reliant on the case definitions of sepsis used by
the authors of the individual studies. The sizes of studies
ranged from 25 to 198. Table 1 presents the characteristics
of the 11 randomized controlled trials which were con-
ducted in Europe, Brazil, or Asia. Most of the randomized
controlled trials were single center, except two trials were
multicentre studies [12, 13]. Additional file 1: Table S1
shows detailed information about the quality assessment
of the included studies, including the Jadad score and the
results of allocation concealment.
Effect of omega-3 fatty acids on mortality
Mortality was reported in ten studies, we combined
these trials in the mortality analyses. A fixed effect
model was used, as no heterogeneity was observed
across the trials (I2 = 0 %; Fig. 2). Our meta-analysis
showed that omega-3 fatty acids did not reduce mortal-
ity (risk ratio 0.84; 95 % CI: 0.67 to 1.05, P = 0.12; Fig. 2).
However, a publication bias may exist in the meta-
Fig. 1 Flowchart shows literature evaluated at each stage of
the meta-analysis
Table 1 Details of included trials
Author Population Route of
Administration
Details of administration Mortality
Study Control
Shirai, 2015 1 center, 46 patients,
sepsis-induced ARDS
EN Oxepa Ensure Liquid 60 days
Hall, 2015 1 center, 60 patients, sepsis PN Omegaven standard medical care 28 days
Burkhart, 2014 1 center, 50 patients, sepsis PN Omegaven standard treatment Hospital
Gultekin, 2014 1 center, 58 patients, severe
sepsis or septic shock
PN Omegaven + ClinOleic ClinOleic Unspecified
Pontes-Arruda, 2011 5 centers, 115 patients, early
stages of sepsis
EN Oxepa Ensure Plus HN 28 days
Grau-Carmona, 2011 11 centers, 198 patients, septic
patients with ALI or ARDS
EN Oxepa Ensure Plus HN Unspecified
Khor, 2011 1 center, 28 patients, severe sepsis PN Omegaven normal saline normal saline
Barbosa, 2010 1 center, 25 patients, sepsis or SIRS PN Lipolus NuTRIflex Lipid Special 28 days
Friesecke, 2008 1 center, 166 patients, critically
ill patients (115 SIRS, 51 non-SIRS)
PN Omegaven + Lipofundin Lipofundin 28 days
Pontes-Arruda, 2006 1 center, 165 patients, severe sepsis
or septic shock
EN EPA-GLA enriched diet Control Diet 28 days
Grecu, 2003 1 center, 54 (15 in ICU) patients,
abdominal sepsis
PN Omegaven + LCT LCT ICU
ARDS acute respiratory distress syndrome, ALI acute lung injury, SIRS Systemic inflammatory response syndrome, EN enteral nutrition, PN parenteral nutrition, LCT
Long-chain triglycerides, EPA eicosapentaenoic acid, GLA gamma-linolenic acid, Ensure Liquid, Ensure Plus HN, omega-3 fatty acids deficiency nutrition for EN;
Lipofundin, NuTRIflex Lipid Special, ClinOleic, omega-3 fatty acids deficiency nutrition for PN; Oxepa, omega-3 fatty acids enriched nutrition for EN; Omegaven,
omega-3 fatty acids enriched nutrition for PN
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analysis that was focused on the mortality by the funnel
plot analysis (Fig. 3).
Effect of omega-3 fatty acids on infectious complications
or the duration of mechanical ventilation
Infectious complications were reported in five studies
(Additional file 2: Table S2), we combined these trials in
the meta-analysis. Our meta-analysis showed that
omega-3 fatty acids did not affect infectious complica-
tions (risk ratio 0.95; 95 % CI: 0.72 to 1.25, P = 0.70;
Fig. 4).
The duration of mechanical ventilation was reported
in seven studies, but the data from five of them could
be combined in the meta-analysis (Additional file 2:
Table S2). Our meta-analysis showed that omega-3 fatty
acids can reduce the duration of mechanical ventilation
(WMD= −3.82; 95 % CI: −4.61 to −3.04; P < 0.00001;
Fig. 5). However, a heterogeneity was found across the tri-
als (I2 = 40 %; Fig. 5). Sensitivity analyses suggested that
no benefit on the duration of mechanical ventilation was
observed among the remaining studies after excluded one
study [8] (I2 = 0 %; Additional file 3: Figure 5S). Thus, this
result should be interpreted with caution.
Effect of omega-3 fatty acids on the length of ICU or
hospital stay
Although 9 trials presented the length of ICU stay, the
data from six of them could be analyzed in the meta-
analysis (Additional file 4: Table S3). A marked hetero-
geneity was observed across the trial (I2 = 87 %;
Additional file 5: Figure 1S1). Additional file 5: Figure 1S1
shows the result from a randomized effect model that in-
vestigates the effect of omega-3 fatty acids on the length
of ICU stay. According to our results, omega-3 fatty acids
did not affect the length of ICU stay (WMD= −2.70; 95 %
CI: −6.40 to 1.00, P = 0.15; Additional file 5: Figure 1S1).
Sensitivity analyses were conducted to explore potential
sources of heterogeneity. A mild heterogeneity was ob-
served among the remaining studies (I2 = 33 %; Additional
file 6: Figure 1S2), after exclusion of two trial [8, 26]. But
the exclusion of the trial [8, 26] did not materially alter
the effect of omega-3 fatty acids on the length of ICU stay
(Additional file 6: Figure 1S2).
Fig. 2 Forest plots show the effect of omega-3 fatty acids on mortality in septic patients
Fig. 3 Funnel plots analysis of mortality in trials of omega-3 fatty acids nutrition in septic patients. Each point represents one trial
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We combined four trials in the length of hospital stay
analysis. Our meta-analysis showed that omega-3 fatty
acids did not affect the length of hospital stay (WMD =
−2.82; 95 % CI: −9.88 to 4.23, P = 0.43; Additional file 7:
Figure 2S1). A significantly heterogeneity was observed
across the trial (I2 = 93 %; Additional file 7: Figure 2S1).
Our sensitivity analyses suggested that after exclusion
of one trial [26], no heterogeneity was observed
among the remaining studies (I2 = 0 %; Additional file 8:
Figure 2S2). But the exclusion of the trial [26] did not ma-
terially alter the effect of omega-3 fatty acids on the length
of hospital stay (WMD =0.96; 95 % CI: −1.55 to 3.48,
P = 0.45; Additional file 8: Figure 2S2).
Subgroup analysis
Subgroup analysis was performed to investigate that
whether the effect of omega-3 fatty acids enriched nutri-
tion on sepsis was influenced by its dose and composition,
or a different administration route (either parenteral or
enteral pathway). Our meta-analysis indicated that neither
parenteral (risk ratio 0.84; 95 % CI: 0.61 to 1.14, P = 0.26;
Additional file 9: Figure 3S1; included 6 trials) nor enteral
(risk ratio 0.84; 95 % CI: 0.61 to 1.16, P = 0.29; Additional
file 10: Figure 3S2; included 4 studies) omega-3 fatty acids
nutrition influenced mortality in septic patients.
During the 11 trials included in the present meta-
analysis, six trials investigated Omegaven (a commer-
cially available omega-3 fatty acids enriched parenteral
nutrition), however, only five of them reported mortality
(risk ratio 0.84; 95 % CI: 0.61 to 1.16, P = 0.30;
Additional file 11: Figure 4S1); Oxepa (a commercially
available omega-3 fatty acids enriched enteral nutrition)
was studied in three trials (risk ratio 1.03; 95 % CI: 0.66
to 1.62, P = 0.89; Additional file 12: Figure 4S2), one
studies investigated self-made omega-3 fatty acids
enriched enteral nutrition (risk ratio 0.63; 95 % CI: 0.39
to 1.00; Fig. 2) as well as one trial investigated Lipolus (a
commercially available omega-3 fatty acids enriched par-
enteral nutrition, risk ratio 0.77; 95 % CI: 0.25 to 2.34;
Fig. 2). Our meta-analysis suggested that none of the
four type of omega-3 fatty acids enriched nutrition has a
benefit on mortality.
Discussion
The primary outcome of our meta-analysis suggested
that omega-3 fatty acids nutrition has no benefit on re-
duction of mortality in septic patient. The secondary
outcomes suggested that omega-3 fatty acids nutrition
did not increase the infectious complications. Neverthe-
less, omega-3 fatty acids nutrition failed to show a bene-
ficial effect on the length of hospital stay, or intensive
care stay. However, the duration of mechanical ventila-
tion was markedly reduced by omega-3 fatty acids.
A previous systematic review and meta-analysis of par-
enteral omega-3 fatty acids for sepsis found a beneficial
effect on mortality (risk ratio 0.77; 95 % CI: 0.59 to 0.99,
P = 0.04; 12 trials, 721 patients). Our study is not con-
sistent with this work. The difference of enrolled trials
Fig. 4 Forest plots show the effect of omega-3 fatty acids on infectious complications in septic patients
Fig. 5 Forest plots show the effect of omega-3 fatty acids on the duration of mechanical ventilation in septic patients
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may attribute to the inconsistent result between our
study and the previous meta-analysis. In the present
meta-analysis, we also investigated that whether the ef-
fect of omega-3 fatty acids on sepsis was different when
it was administrated via parenteral or enteral pathway,
and whether the dose and composition of omega-3 fatty
acids nutrition could influence its effect.
Secondary organ dysfunction is a key factor that trig-
gered death in septic patients [1, 3–5]. It has been found
that omega-3 fatty acids nutrition may prevent new
organ dysfunction in three randomized controlled trials
with 278 cases of sepsis [9, 12, 17] (two trials investi-
gated mild or early sepsis [9, 12], one study with severe
sepsis or septic shock [17]). Thus, it seems that the
omega-3 fatty acids may play a benefit on sepsis through
inhibit new organ dysfunction. SOFA scores, an indica-
tor of secondary organ dysfunction, were reported in
three trials [8, 9, 13]. As it was unable to obtain explicit
data on SOFA scores that could be combined in the
meta-analysis, we did not analyze the effect of omega-3
fatty acids on SOFA scores. It seems that omega-3 fatty
acids may have potential benefit on new organ dysfunc-
tion; we suggested that a further study focus on the ef-
fect of omega-3 fatty acids on sepsis should investigate
secondary organ dysfunction. Mechanical ventilation is a
lifesaving strategy for critical ill patients. However, its
adverse effects such as ventilation-induced lung injury,
and ventilator associated pneumonia are life threatening.
Our meta-analysis included 5 trials (Fig. 5) suggested
that omega-3 fatty acids can reduce the duration of
mechanical ventilation in septic patient. This result is
not consistent with a previous meta-analysis [18] which
included two studies [15, 16]. Nevertheless, heterogen-
eity was found across the trials. Thus, the result should
be interpreted with caution.
The potential mechanism that could possibly explain
why omega-3 fatty acids may not be beneficial in septic
patients was as follows: Firstly, sepsis is a severe disease
with a high mortality [1, 3–5]. A number of factors such
as a history of severe diseases, or divergence of pathogen
may influence the clinic outcome. Septic patients often
complicated with organ dysfunction or shock which may
further elevate mortality. The included trials in our
meta-analysis suggested that a number of patients diag-
nosed as sepsis were complicated organ dysfunction or
shock. Acute respiratory distress syndrome, an inflam-
mation disease with mortality over 40 %, is a common
secondary organ dysfunction in septic patients [1, 3–5,
28]. A previous meta-analysis focused on the effect of
omega-3 fatty acids on acute respiratory distress syn-
drome (ARDS) reported that it has no effect on reduc-
tion of 28-day mortality [29]. The failure on the
improvement of complications by omega-3 fatty acids
seems to have limited impact on septic patients’ survival.
Secondly, the rational of omega-3 fatty acids nutrition as
an adjunctive therapy for sepsis is partly based on its
anti-inflammatory and immunomodulating features.
However, the mild anti-inflammatory effect of omega-3
fatty acids might not lead to improve in outcome. It has
been reported that even a delay of antibiotics treatment
may cause a significant increased mortality in patients
with sepsis [30].
A previous meta-analysis [29] suggested that a high fat
formula used in control group which may contribute to
an increased mortality could be the reason that a re-
duced mortality was observed in study group. It is sug-
gested that the high fat formula may have pro-
inflammatory features, and resulting in a worsened clin-
ical outcome [31]. It seems that clinical outcomes could
be influenced by the dose and composition of nutrition.
As the dose and composition of omega-3 fatty acids nu-
trition agent were divergent in studies, we are interested
in that whether the effect of omega-3 fatty acids on sep-
sis may be affected by the difference of dose and com-
position. Therefore, we examined trials testing different
type of omega-3 fatty acids agent separately. Our sub-
group meta-analysis indicated that the effect of omega-3
fatty acids on mortality in septic patients was not influ-
enced by its dose and composition.
We are also interested in that whether the difference
between parenteral and enteral administration may in-
fluence the effect of omega-3 fatty acids on septic pa-
tients. In a previous meta-analysis [32] included three
trials that reported a protective effect of omega-3 fatty
acids on ARDS, the administration strategy was enteral
nutrition. Our subgroup meta-analysis suggested that
the mortality in septic patients was not influenced by
omega-3 fatty acids that administrated through either
parenteral or enteral pathway. This result is consistent
with a previous meta-analysis that focuses on the effect
of omega-3 fatty acids on critically ill patients [33].
These results suggested that the administration strategy
may not be the key factor that influenced the effect of
omega-3 fatty acids on sepsis or other critically ill
patients.
There are some limitations in our meta-analysis. One
potential limitation of the present meta-analysis was the
asymmetric funnel plot that suggested publication bias
may exist. It is possibly that the present meta-analysis
did not include all of the trials, as we restricted the lit-
erature language to English, and other database except
the PubMed was not adopted. Meanwhile, the small
sample size may also have been a limitation, which may
have lowered the statistical power. Furthermore, a
marked heterogeneity was detected when the length of
ICU or hospital stay was analyzed.
In brief, although our meta-analysis suggested that
omega-3 fatty acids failed to reduce overall mortality in
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septic patients, a tendency toward a reduction in mortal-
ity should not be neglected (risk ratio 0.84; 95 % CI: 0.67
to 1.05, P = 0.12). Thus, future large scale, multicentre
investigation is still required to draw a conclusion.
Conclusions
Omega-3 fatty acids confer no mortality benefit but are
associated with a reduction in mechanical ventilation
duration in septic patients. However, low sample size
and heterogeneity of the cohorts included in this analysis
limits the generalizability of our findings.
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